NCT04091061View on ClinicalTrials.gov

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

PF-06865571 100 mg

PF-06865571 in 100 mg oral tablet will be administered on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami Division of Clinical Pharmacology, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04091061 - Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects | Biotech Hunter | Biotech Hunter